Luis Alvarez, MD
Nephrology · Palo Alto, CANPI 1487685368
Payments from drug & device makers
Across 1,645 payments — averaging $1103.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$719K
- Amgen$414K
- Bayer$200K
- Fresenius USA Marketing, Inc.$124K
- Calliditas Therapeutics US Inc.$118K
- Akebia Therapeutics Inc$75K
- plus $165K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 41 | $719,291 |
| Amgen | 491 | $413,803 |
| Bayer | 204 | $200,197 |
| Fresenius USA Marketing, Inc. | 225 | $123,591 |
| Calliditas Therapeutics US Inc. | 136 | $117,837 |
| Akebia Therapeutics Inc | 103 | $75,397 |
| Vifor Pharma, Inc. | 165 | $59,319 |
| Travere Therapeutics, Inc. | 100 | $45,752 |
| Novartis | 38 | $22,599 |
| Kyowa Kirin, Inc. | 26 | $18,757 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $9,363 |
| AstraZeneca(2 entities) | 40 | $3,251 |
| Otsuka America Pharmaceutical, Inc. | 15 | $2,185 |
| Sanofi | 1 | $1,841 |
| Lilly USA, LLC | 7 | $283 |
| GSK | 10 | $232 |
| Edwards Lifesciences | 1 | $202 |
| Ardelyx, Inc. | 8 | $185 |
| Aurinia Pharma U.S., Inc. | 3 | $156 |
| Bard Peripheral Vascular, Inc. | 1 | $150 |
| Apellis Pharmaceuticals, Inc. | 1 | $145 |
| Abiomed | 2 | $131 |
| Boehringer Ingelheim | 4 | $123 |
| ANI Pharmaceuticals, Inc. | 5 | $88 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Veloxis Pharmaceuticals, Inc. | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
How this compares
$1,814,956 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Palo Alto
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.